Emile Voest
More and more cancer drugs are only suitable for a small group of patients. However, we are often not capable to find these patients. That is why every patient with metastatic cancer should be genetically screened before starting treatment.
Back to newsMore news
Clinical Cancer Genomics conference, March 20-21 2025, Amsterdam
We are pleased to announce that registration for this novel exciting meeting focused on cancer whole genome and transcriptome sequencing …
From Spreadsheets to Digital Convenience: Hartwig Goes Live With Its Customer Portal
Hartwig Medical Foundation (Hartwig) recently launched its new portal for submitting requests for WGS analysis. For hospitals, this is an important enhancement to …
Patients can benefit from whole genome sequencing for immunotherapy
Immunotherapy is an effective treatment for many people with cancer. The number of abnormalities in the DNA of the tumor in …
The complete DNA test is an additional tool to help us discover the origin of the cancer in patients with CUP, often enabling us to identify this primary tumor. In addition, the test often reveals new options for targeted treatment.